Previous 10 | Next 10 |
Coronavirus Pandemic Junshi Biosciences [HK:1877] out-licensed ex-China rights for a therapeutic antibody aimed at preventing and treating COVID-19 to Eli Lilly (LLY) (see story ). JS016 is a recombinant fully human monoclonal neutralizing antibody that is specific to the SARS-CoV-2 surface...
BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, g...
The Biomedical Advanced Research and Development Authority (BARDA) has initiated funding Paratek Pharmaceuticals (NASDAQ: PRTK ) to support all of the FDA post-marketing requirements for NUZYRA approval including pneumonia and pediatric studies as well as the five-year post-marketing bacte...
BOSTON, April 02, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, go...
The Biomedical Advanced Research and Development Authority (BARDA) has initiated funding to Paratek Pharmaceuticals (NASDAQ: PRTK ) to support the onshoring of manufacturing activities for NUZYRA. More news on: Paratek Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ...
BOSTON, April 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for civilia...
Paratek Pharmaceuticals (NASDAQ: PRTK ) announces that the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) has filed an application with the FDA seeking emergency use authorization to use antibiotic Nuzyra (omadacycline...
BOSTON, March 10, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, go...
[Man] progresses in all things by resolutely making a fool of himself. ”― George Bernard Shaw, Advice to a Young Critic Paratek Pharmaceuticals ( PRTK ) reported solid Q4 results after the bell Tuesday. This ' best of breed ' antibiotic concern is seeing some enthusiasm in...
The following slide deck was published by Paratek Pharmaceuticals, Inc. in conjunction with their 2019 Q4 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Paratek Pharmaceuticals Inc. Company Name:
PRTK Stock Symbol:
NASDAQ Market:
Paratek Pharmaceuticals Inc. Website:
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Paratek Pharmaceuticals Inc. (PRTK) is expected to report $-0.25 for Q3 2023
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military ...